Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction
PW Armstrong,
RS Baigrie,
PA Daly,
A Haq,
M Gent,
RS Roberts,
MR Freeman,
R Burns,
P Liu,
and
CD Morgan
Department of Medicine, University of Toronto, Ontario, Canada.
The efficacy and safety of recombinant tissue plasminogen activator (rt-PA) administered on a dosing per weight basis was evaluated in a randomized, placebo-controlled, double-blind trial in 115 patients with acute myocardial infarction. The principal outcomes were global and regional left ventricular function in the distribution of the qualifying myocardial infarction, determined 9 days after the onset of symptoms. Global and regional ejection fraction values were significantly better for patients treated with rt-PA than for placebo-treated patients (the differences were 5.8 +/- 2.7% units [p = 0.017] and 7.1 +/- 3.1% units [p = 0.012], respectively). This benefit was also evident from visual assessment of left ventricular segmental wall motion. After adjustment for differences in important prognostic variables at baseline, the estimates of treatment effect were 4.0 +/- 2.4% units (p = 0.048) for global and 4.3 +/- 2.6% units (p = 0.047) for regional ejection fraction. Early patency of the infarct-related vessel was demonstrable in 7 (29%) of 24 placebo-treated patients and 18 (78%) of 23 rt-PA-treated patients, whereas 15 (56%) of 27 patients in the placebo group and 23 (72%) of 32 in the rt-PA group had a patent infarct-related vessel at hospital day 9. There was no significant difference in irreversible or reversible defect size as assessed by thallium scintigraphy on day 7.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:

|
 |

|
 |
 
J. D. Maclay, D. A. McAllister, N. L. Mills, F. P. Paterson, C. A. Ludlam, E. M. Drost, D. E. Newby, and W. MacNee
Vascular Dysfunction in Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med.,
September 15, 2009;
180(6):
513 - 520.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. D. Robinson, C. A. Ludlam, N. A. Boon, and D. E. Newby
Endothelial Fibrinolytic Capacity Predicts Future Adverse Cardiovascular Events in Patients With Coronary Heart Disease
Arterioscler Thromb Vasc Biol,
July 1, 2007;
27(7):
1651 - 1656.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. J. Oliver, D. J. Webb, and D. E. Newby
Stimulated Tissue Plasminogen Activator Release as a Marker of Endothelial Function in Humans
Arterioscler Thromb Vasc Biol,
December 1, 2005;
25(12):
2470 - 2479.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. N. Witherow, P. Dawson, C. A. Ludlam, K. A. A. Fox, and D. E. Newby
Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy
J. Am. Coll. Cardiol.,
September 4, 2002;
40(5):
961 - 966.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Labinjoh, D. E. Newby, M. P. Pellegrini, N. R. Johnston, N. A. Boon, and D. J. Webb
Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition
J. Am. Coll. Cardiol.,
November 1, 2001;
38(5):
1402 - 1408.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. M. Ohman, R. A. Harrington, C. P. Cannon, G. Agnelli, J. A. Cairns, and J.W. Kennedy
Intravenous Thrombolysis in Acute Myocardial Infarction
Chest,
January 1, 2001;
119(2009):
253S - 277S.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. E. Newby, R. A. Wright, C. Labinjoh, C. A. Ludlam, K. A. A. Fox, N. A. Boon, and D. J. Webb
Endothelial Dysfunction, Impaired Endogenous Fibrinolysis, and Cigarette Smoking : A Mechanism for Arterial Thrombosis and Myocardial Infarction
Circulation,
March 23, 1999;
99(11):
1411 - 1415.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. E Newby, R. A Wright, P. Dawson, C. A Ludlam, N. A Boon, K. A.A Fox, and D. J Webb
The L-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man
Cardiovasc Res,
May 1, 1998;
38(2):
485 - 492.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Kellett and J. Clarke
Comparison of "Accelerated" Tissue Plasminogen Activator with Streptokinase for Treatment of Suspected Myocardial Infarction
Med Decis Making,
October 1, 1995;
15(4):
297 - 310.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Sherry and V. J. Marder
Streptokinase and Recombinant Tissue Plasminogen Activator (rt-PA) Are Equally Effective in Treating Acute Myocardial Infarction
Ann Intern Med,
March 1, 1991;
114(5):
417 - 423.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C. D. Naylor and S. B. Jaglal
Impact of Intravenous Thrombolysis on Short-term Coronary Revascularization Rates: A Meta-analysis
JAMA,
August 8, 1990;
264(6):
697 - 702.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D. W. Krichbaum and D. A. Trivedi
Thrombolytic Therapy in Acute Myocardial Infarction
Journal of Pharmacy Practice,
January 1, 1990;
3(5):
332 - 348.
[PDF]
|
 |
|
|